WO2007087612A3 - Detection and diagnosis of smoking related cancers - Google Patents

Detection and diagnosis of smoking related cancers Download PDF

Info

Publication number
WO2007087612A3
WO2007087612A3 PCT/US2007/061073 US2007061073W WO2007087612A3 WO 2007087612 A3 WO2007087612 A3 WO 2007087612A3 US 2007061073 W US2007061073 W US 2007061073W WO 2007087612 A3 WO2007087612 A3 WO 2007087612A3
Authority
WO
WIPO (PCT)
Prior art keywords
related cancers
diagnosis
smoking related
detection
probes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/061073
Other languages
French (fr)
Other versions
WO2007087612A2 (en
WO2007087612A8 (en
Inventor
Ruth Katz
Feng Jiang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
University of Texas at Austin
Original Assignee
University of Texas System
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, University of Texas at Austin filed Critical University of Texas System
Priority to EP07762399A priority Critical patent/EP1989329A2/en
Publication of WO2007087612A2 publication Critical patent/WO2007087612A2/en
Publication of WO2007087612A3 publication Critical patent/WO2007087612A3/en
Anticipated expiration legal-status Critical
Publication of WO2007087612A8 publication Critical patent/WO2007087612A8/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Gene probes for specific regions of chromosomes (1, 3, 9, 10 and 17) are now shown to be useful in the diagnosis and prognosis of smoking related cancers such as non-small cell lung cancer (NSCLC). For example, these probes can be used with fluorescence in situ hybridization (FISH), and used to stratify smokers into high and low risk groups, to determine susceptibility to the development of smoking related cancers, to predict cancer progression and treatment efficacy, and to rule out other diseases.
PCT/US2007/061073 2006-01-25 2007-01-25 Detection and diagnosis of smoking related cancers Ceased WO2007087612A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP07762399A EP1989329A2 (en) 2006-01-25 2007-01-25 Detection and diagnosis of smoking related cancers

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76180606P 2006-01-25 2006-01-25
US60/761,806 2006-01-25

Publications (3)

Publication Number Publication Date
WO2007087612A2 WO2007087612A2 (en) 2007-08-02
WO2007087612A3 true WO2007087612A3 (en) 2007-10-11
WO2007087612A8 WO2007087612A8 (en) 2008-11-27

Family

ID=38235409

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/061073 Ceased WO2007087612A2 (en) 2006-01-25 2007-01-25 Detection and diagnosis of smoking related cancers

Country Status (3)

Country Link
US (1) US20070218480A1 (en)
EP (1) EP1989329A2 (en)
WO (1) WO2007087612A2 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8137912B2 (en) 2006-06-14 2012-03-20 The General Hospital Corporation Methods for the diagnosis of fetal abnormalities
US8168389B2 (en) 2006-06-14 2012-05-01 The General Hospital Corporation Fetal cell analysis using sample splitting
US8195415B2 (en) 2008-09-20 2012-06-05 The Board Of Trustees Of The Leland Stanford Junior University Noninvasive diagnosis of fetal aneuploidy by sequencing
US8921102B2 (en) 2005-07-29 2014-12-30 Gpb Scientific, Llc Devices and methods for enrichment and alteration of circulating tumor cells and other particles
US10591391B2 (en) 2006-06-14 2020-03-17 Verinata Health, Inc. Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats
US10704090B2 (en) 2006-06-14 2020-07-07 Verinata Health, Inc. Fetal aneuploidy detection by sequencing

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009046450A1 (en) * 2007-10-05 2009-04-09 The Regents Of The University Of California Aromatase expression predicts survival in women with non-small cell lung cancer
US20100317002A1 (en) * 2007-10-11 2010-12-16 Bioview Ltd. Methods and kits for diagnosing lung cancer
WO2009117595A2 (en) * 2008-03-19 2009-09-24 The Board Of Regents Of The University Of Texas System Sequence variations on chromosome 15 predicting risk for lung cancer
CA2722424A1 (en) * 2008-04-25 2009-10-29 Integrated Bioscience Solutions, Llc Cytological methods for detecting cancer
US8785131B2 (en) * 2008-11-11 2014-07-22 Abbott Laboratories Prognostic test for early stage non small cell lung cancer (NSCLC)
JP2013545756A (en) * 2010-11-16 2013-12-26 グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッド Administration and treatment methods
EP2607494A1 (en) * 2011-12-23 2013-06-26 Philip Morris Products S.A. Biomarkers for lung cancer risk assessment
RU2530170C1 (en) * 2013-03-27 2014-10-10 Михаил Аркадьевич Шурдов Method of detecting stem cancer cells
AU2015220749B2 (en) * 2014-02-21 2020-12-24 Ventana Medical Systems, Inc. Single-stranded oligonucleotide probes for chromosome or gene copy enumeration
CN107208151A (en) * 2014-12-10 2017-09-26 得克萨斯州大学系统董事会 Circulating tumor and cancer stem cell detection using genome-specific probes
US20230266325A1 (en) 2020-06-30 2023-08-24 Lunglife Ai, Inc. Methods for detecting lung cancer
WO2023230531A1 (en) 2022-05-24 2023-11-30 Lunglife Ai, Inc. Methods for detecting circulating genetically abnormal cells

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002012563A2 (en) * 2000-08-04 2002-02-14 Board Of Regents, The University Of Texas System Detection and diagnosis of smoking related cancers

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6475720B1 (en) * 1986-01-16 2002-11-05 The Regents Of The University Of California Chromosome-specific staining to detect genetic rearrangements associated with chromosome 3 and/or chromosome 17
US6344315B1 (en) * 1986-01-16 2002-02-05 The Regents Of The University Of California Chromosome-specific staining to detect genetic rearrangements associated with chromosome 3 and/or chromosome 17
US5670314A (en) * 1994-02-22 1997-09-23 Regents Of The University Of California Genetic alterations that correlate with lung carcinomas
US6689561B1 (en) * 1994-04-14 2004-02-10 The Regents Of The University Of California Tumor suppressor gene and methods for detection of cancer, monitoring of tumor progression and cancer treatment
US20020137030A1 (en) * 1995-06-30 2002-09-26 John Hopkins University School Of Medicine Method of detection of neoplastic cells
US6291163B1 (en) * 1996-08-28 2001-09-18 The Johns Hopkins University School Of Medicine Method for detecting cell proliferative disorders
US20030138928A1 (en) * 1997-08-26 2003-07-24 Carson Dennis A. Tumor suppressor gene and methods for detection of cancer, monitoring of tumor progression and cancer treatment
US6576420B1 (en) * 1998-06-23 2003-06-10 Regents Of The University Of California Method for early diagnosis of, and determination of prognosis in, cancer
US6174681B1 (en) * 1999-03-05 2001-01-16 Mayo Foundation For Medical Education And Research Method and probe set for detecting cancer
US6774226B1 (en) * 1999-11-30 2004-08-10 Ludwig Institute For Cancer Research Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof
US6846650B2 (en) * 2000-10-25 2005-01-25 Diadexus, Inc. Compositions and methods relating to lung specific genes and proteins
ES2372007T3 (en) * 2001-02-20 2012-01-12 Vysis, Inc. METHODS AND PROBES FOR DETECTION OF CANCER.
US20030119080A1 (en) * 2001-10-15 2003-06-26 Mangano Joseph A. Strategies for the identification and isolation of cancer stem cells and non-cancerous stem cells

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002012563A2 (en) * 2000-08-04 2002-02-14 Board Of Regents, The University Of Texas System Detection and diagnosis of smoking related cancers

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
BARKAN GULIZ A ET AL: "Comparison of molecular abnormalities in bronchial brushings and tumor touch preparations - Potential use of fluorescence in situ hybridization to identify predictive markers in early-stage lung carcinomas", CANCER, vol. 105, no. 1, 25 February 2005 (2005-02-25), pages 35 - 43, XP002443722, ISSN: 0008-543X *
BROCK JO-ANN K ET AL: "Detection of numerical chromosome anomalies in interphase cells of ovarian carcinomas using fluorescence in situ hybridization", GENES CHROMOSOMES AND CANCER, vol. 16, no. 2, 1996, pages 120 - 129, XP002443721, ISSN: 1045-2257 *
DANIELY ET AL: "Combined analysis of morphology and fluorescence in situ hybridization significantly increases accuracy of bladder cancer detection in voided urine samples", UROLOGY, BELLE MEAD, NJ, US, vol. 66, no. 6, December 2005 (2005-12-01), pages 1354 - 1359, XP005212547, ISSN: 0090-4295 *
FURLAN DANIELA ET AL: "Allelotypes and fluorescence in situ hybridization profiles of poorly differentiated endocrine carcinomas of different sites.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH 1 MAR 2005, vol. 11, no. 5, 1 March 2005 (2005-03-01), pages 1765 - 1775, XP002443718, ISSN: 1078-0432 *
HOFMANN HANS-STEFAN ET AL: "Matrix metalloproteinase-12 expression correlates with local recurrence and metastatic disease in non-small cell lung cancer patients.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH 1 FEB 2005, vol. 11, no. 3, 1 February 2005 (2005-02-01), pages 1086 - 1092, XP002443725, ISSN: 1078-0432 *
JIANG FENG ET AL: "Surfactant protein A gene deletion and prognostics for patients with stage I non-small cell lung cancer.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH 1 AUG 2005, vol. 11, no. 15, 1 August 2005 (2005-08-01), pages 5417 - 5424, XP002443724, ISSN: 1078-0432 *
KLEIST BRITTA ET AL: "Multiple chromosomal underrepresentations detected by interphase cytogenetics: Possible prognostic markers in head and neck tumors?", PATHOLOGY AND ONCOLOGY RESEARCH, vol. 7, no. 1, 2001, pages 28 - 32, XP002443720, ISSN: 1219-4956 *
LINGLE WILMA L ET AL: "Centrosome amplification drives chromosomal instability in breast tumor development", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 99, no. 4, 19 February 2002 (2002-02-19), pages 1978 - 1983, XP002443719, ISSN: 0027-8424 *
SCULLY C ET AL: "Genetic aberrations in oral or head and neck squamous cell carcinoma 2: chromosomal aberrations", ORAL ONCOLOGY, ELSEVIER SCIENCE, OXFORD, GB, vol. 36, no. 4, July 2000 (2000-07-01), pages 311 - 327, XP004286698, ISSN: 1368-8375 *
VIRMANI A K ET AL: "Comparison between fluorescence in situ hybridization and classical cytogenetics in human tumors.", ANTICANCER RESEARCH 1998 MAY-JUN, vol. 18, no. 3A, May 1998 (1998-05-01), pages 1351 - 1356, XP009087137, ISSN: 0250-7005 *
WANG HUIJUN ET AL: "Overexpression of S100A2 protein as a prognostic marker for patients with stage I non small cell lung cancer.", INTERNATIONAL JOURNAL OF CANCER. JOURNAL INTERNATIONAL DU CANCER 20 AUG 2005, vol. 116, no. 2, 20 August 2005 (2005-08-20), pages 285 - 290, XP002443723, ISSN: 0020-7136 *

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8921102B2 (en) 2005-07-29 2014-12-30 Gpb Scientific, Llc Devices and methods for enrichment and alteration of circulating tumor cells and other particles
US11674176B2 (en) 2006-06-14 2023-06-13 Verinata Health, Inc Fetal aneuploidy detection by sequencing
US9273355B2 (en) 2006-06-14 2016-03-01 The General Hospital Corporation Rare cell analysis using sample splitting and DNA tags
US10591391B2 (en) 2006-06-14 2020-03-17 Verinata Health, Inc. Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats
US8372584B2 (en) 2006-06-14 2013-02-12 The General Hospital Corporation Rare cell analysis using sample splitting and DNA tags
US8137912B2 (en) 2006-06-14 2012-03-20 The General Hospital Corporation Methods for the diagnosis of fetal abnormalities
US8168389B2 (en) 2006-06-14 2012-05-01 The General Hospital Corporation Fetal cell analysis using sample splitting
US9017942B2 (en) 2006-06-14 2015-04-28 The General Hospital Corporation Rare cell analysis using sample splitting and DNA tags
US11781187B2 (en) 2006-06-14 2023-10-10 The General Hospital Corporation Rare cell analysis using sample splitting and DNA tags
US9347100B2 (en) 2006-06-14 2016-05-24 Gpb Scientific, Llc Rare cell analysis using sample splitting and DNA tags
US11261492B2 (en) 2006-06-14 2022-03-01 The General Hospital Corporation Methods for the diagnosis of fetal abnormalities
US10704090B2 (en) 2006-06-14 2020-07-07 Verinata Health, Inc. Fetal aneuploidy detection by sequencing
US10041119B2 (en) 2006-06-14 2018-08-07 Verinata Health, Inc. Methods for the diagnosis of fetal abnormalities
US10155984B2 (en) 2006-06-14 2018-12-18 The General Hospital Corporation Rare cell analysis using sample splitting and DNA tags
US10435751B2 (en) 2006-06-14 2019-10-08 Verinata Health, Inc. Methods for the diagnosis of fetal abnormalities
US8682594B2 (en) 2008-09-20 2014-03-25 The Board Of Trustees Of The Leland Stanford Junior University Noninvasive diagnosis of fetal aneuploidy by sequencing
US10669585B2 (en) 2008-09-20 2020-06-02 The Board Of Trustees Of The Leland Stanford Junior University Noninvasive diagnosis of fetal aneuploidy by sequencing
US9404157B2 (en) 2008-09-20 2016-08-02 The Board Of Trustees Of The Leland Stanford Junior University Noninvasive diagnosis of fetal aneuploidy by sequencing
US9353414B2 (en) 2008-09-20 2016-05-31 The Board Of Trustees Of The Leland Stanford Junior University Noninvasive diagnosis of fetal aneuploidy by sequencing
US8296076B2 (en) 2008-09-20 2012-10-23 The Board Of Trustees Of The Leland Stanford Junior University Noninvasive diagnosis of fetal aneuoploidy by sequencing
US8195415B2 (en) 2008-09-20 2012-06-05 The Board Of Trustees Of The Leland Stanford Junior University Noninvasive diagnosis of fetal aneuploidy by sequencing
US12054777B2 (en) 2008-09-20 2024-08-06 The Board Of Trustees Of The Leland Standford Junior University Noninvasive diagnosis of fetal aneuploidy by sequencing

Also Published As

Publication number Publication date
WO2007087612A2 (en) 2007-08-02
WO2007087612A8 (en) 2008-11-27
EP1989329A2 (en) 2008-11-12
US20070218480A1 (en) 2007-09-20

Similar Documents

Publication Publication Date Title
WO2007087612A3 (en) Detection and diagnosis of smoking related cancers
Keller et al. Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond
WO2002012563A3 (en) Detection and diagnosis of smoking related cancers
Wouters et al. Comprehensive DNA methylation study identifies novel progression-related and prognostic markers for cutaneous melanoma
Jiang et al. Serum microRNA expression signatures identified from genome‐wide microRNA profiling serve as novel noninvasive biomarkers for diagnosis and recurrence of bladder cancer
Kim et al. High tumour islet macrophage infiltration correlates with improved patient survival but not with EGFR mutations, gene copy number or protein expression in resected non-small cell lung cancer
Barata et al. Next-generation sequencing (NGS) of cell-free circulating tumor DNA and tumor tissue in patients with advanced urothelial cancer: a pilot assessment of concordance
Franchina et al. Circulating miR‐22, miR‐24 and miR‐34a as novel predictive biomarkers to pemetrexed‐based chemotherapy in advanced non‐small cell lung cancer
ES2862331T3 (en) Methods to predict the status of the BRCA1 and BRCA2 genes in a cancer cell
Cai et al. ROS1 fusions in Chinese patients with non-small-cell lung cancer
WO2013033629A3 (en) Methods and compositions for the treatment and diagnosis of colorectal cancer
WO2011056489A3 (en) Diagnostic methods for determining prognosis of non-small cell lung cancer
Shen et al. A three-gene signature as potential predictive biomarker for irinotecan sensitivity in gastric cancer
Spindler et al. KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer
WO2010004591A3 (en) Genetic variants for breast cancer risk assessment
Mannan et al. K‐ras mutations are correlated to lymph node metastasis and tumor stage, but not to the growth pattern of colon carcinoma
WO2007112330A8 (en) Compositions and methods for detection, prognosis and treatment of colon cancer
Xie et al. LncRNA HMlincRNA717 is down-regulated in non-small cell lung cancer and associated with poor prognosis
WO2006089233A3 (en) Methods and systems for diagnosis, prognosis and selection of treatment of leukemia
NZ595993A (en) Method for diagnosis of cancer and monitoring of cancer treatments
WO2010051314A3 (en) Genomic classification of non-small cell lung carcinoma based on patterns of gene copy number alterations
Zhao et al. The rs6983267 SNP and long non‐coding RNA CARLo‐5 are associated with endometrial carcinoma
WO2007124309A3 (en) Methods for detecting mutations in jak2 nucleic acid
CN109563544A (en) Diagnostic assay for urine monitoring of bladder cancer
Chou et al. Genes involved in angiogenesis and mTOR pathways are frequently mutated in Asian patients with pancreatic neuroendocrine tumors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007762399

Country of ref document: EP